Theravance Reports Results from Phase 2B Study 0091 with TD-4208 for COPD, Says Met Primary Efficacy Endpoint

Theravance, Inc. (NASDAQ: THRX ) today announced positive topline results from a dose-ranging 7-day cross-over design Phase 2b study of TD-4208, an investigational long-acting muscarinic antagonist (LAMA), administered once-a-day as a nebulized aqueous solution in patients with moderate to severe chronic obstructive pulmonary disease (COPD). The primary efficacy endpoint in this study was change from